Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Silence Therapeutics plc
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
Today 8:00 EDT
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 15, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
June 27, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
June 24, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
June 20, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
May 16, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
April 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
April 29, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
April 08, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
February 28, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
February 23, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
February 05, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
December 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
November 14, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
November 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 26, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in September Investor Conferences
September 06, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports Second Quarter 2023 Results
August 16, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
July 11, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Reports First Quarter 2023 Results
May 16, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
May 04, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
May 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
April 04, 2023
From
Silence Therapeutics plc
Via
Business Wire
Tickers
SLN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.